chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Extended down into my hand and up into my shoulder; Kinda fluidy; Arm pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm pain), ARTHRALGIA (Extended down into my hand and up into my shoulder) and FLUID RETENTION (Kinda fluidy) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     Concurrent medical conditions included Pelvic fracture.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced PAIN IN EXTREMITY (Arm pain). On an unknown date, the patient experienced ARTHRALGIA (Extended down into my hand and up into my shoulder) and FLUID RETENTION (Kinda fluidy). The patient was treated with OXYCODONE HYDROCHLORIDE, PARACETAMOL (PERCOCET [OXYCODONE HYDROCHLORIDE;PARACETAMOL]) for Pelvic fracture, at a dose of UNK dosage form. At the time of the report, PAIN IN EXTREMITY (Arm pain), ARTHRALGIA (Extended down into my hand and up into my shoulder) and FLUID RETENTION (Kinda fluidy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.
On day 2 patient reported pain, swelling, and redness. Around the infection site. Patient reported that it has not gotten worse on day 3; however was concerned that the infection site felt hard.
IMMEDIATELY AFTER IMZ SHE FELT NAUSEOUS BUT IT RESOLVED.  AT 7 PM SHE FELT NAUSEOUS AND BEGAN VOMITING AS WELL AS DIARRHEA.  SHE FELT VERY COLD AND UNABLE TO WARM UP.  SHE HAD DIFFICULTY SWALLOWING AND FELT AS IF HER "ADAMS APPLE WAS CLOSED".  PATIENT NOTIFIED THE PHARMACY THE NEXT DAY AT 9AM. THE NAUSEA/VOMITING/DIARRHEA/DIFFICULTY SWALLOWING HAD ALL RESOLVED.  SHE WAS STILL FEELING CHILLED AND A LITTLE WEAK BUT MUCH BETTER THAN THE DAY OF THE IMMUNIZATION. SHE DID NOT GO TO THE HOSPITAL.
Patient reports lightheaded, difficulty breathing, and rapid heart beat 5 minutes after receiving covid vaccine. Vital signs taken reveal elevated blood pressure and heart rate. Patient transported to emergency department for further evaluation.
This spontaneous report as received from a healthcare worker refers to a 4 year old patient of unknown gender. On 22-DEC-2014 the patient was vaccinated with the second dose of PROQUAD (Merck) which was improperly stored, lot# K007801 with expiration date 29-NOV-2015, 0.5 ml once, subcutaneous. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
arm is a little sore; intense ringing in ears; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in deltoid left, administration date 22Apr2021 16:35 (Lot number: EP7533, Expiration Date: Jul2021) at the age of 57 years as dose 1, single for COVID-19 immunisation. Relevant medical history included: "vision diminishing" (unspecified if ongoing), notes: as he is getting old; "diagnosed as pre-diabetic" (unspecified if ongoing), notes: had a lab thing done. The patient's concomitant medications were not reported. Past drug history included: Lutein for to mitigate his vision diminishing. Vaccination history included: Rubella, for immunization. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "arm is a little sore"; TINNITUS (non-serious), outcome "unknown", described as "intense ringing in ears". Additional information: The vaccine was administered on his left shoulder. The patient does not take aspirin and stated he took an allergy tablet before (unspecified) about more than a week before vaccination. He did not receive any other vaccines within 4 weeks. The events did not result in a physician or emergency room visit. The patient states will not get his second dose if the side effects last.   No follow-up attempts are possible. No further information is expected.
patient continues to have severe left arm pain at the site of the injection, no redness, no swelling, reports a nerve like pain, hot compresses are improving, has full use of arm
Resident reported loose stool, not feeling well, resident complaint of lost taste. Hospitalization on 01/14/2020.
4 mo. 10 minutes post IPV to R leg, DTaP to R leg, and HIB to L leg developed erythematous (blanching) thigh to foot and mildly swollen feet. No wheezing, no SOB, no Swollen face or pharynx. Rxd with Benadryl to resolution.
Mild Pericarditis and Swelling at injection site 6 days after injection from dime size to quarter size overnight. No shortness of breath, tightness in chest and right under the sternum. Rated at 3 out of 10. No edema, fatigue, aches or other symptoms noted when verbally asked. Able to perform ADL's.  Advised to reach out to Primary care physician and seek medical consult. Individual was seen in the ED at the local hospital.
gyneco infection; This spontaneous case was reported by a consumer and describes the occurrence of GENITAL INFECTION FEMALE (gyneco infection) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced GENITAL INFECTION FEMALE (gyneco infection). The patient was treated with CEFALEXIN (KEFLEX [CEFALEXIN]) for Gynecological infection, at an unspecified dose and frequency. At the time of the report, GENITAL INFECTION FEMALE (gyneco infection) outcome was unknown.            No concomitant medications were reported. Patient had mentioned that she was experiencing an gyneco infection and she needed to take an antibiotic.   Most recent FOLLOW-UP information incorporated above includes: On 09-Nov-2021: Follow up received, contains No new information.
The report had been received from a physician via medical representative. The report concerns a 4 years old patient of unknown gender. Concomitant medication, medical history, concurrent diseases were not reported. The patient was received nasal FLUMIST QUADRIVALENT on 29-Oct-2013. The patient was tested positive was flu on 31-Jan-2014. The patient recovered from the event of tested positive for flu A on an unspecified date. The event was considered to be non-serious by the reporter.
Pt devel rash on rt leg Saturday evening size of baseball, hardness @ inject site approx size of golf ball was noted Sunday 28MAR; mom gave Tmepra to pt; pt walking w/sl limp; rt leg appears sl larger than lt from knee to thigh;
About 24hrs after receiving the vaccine I had what felt like a lump in my right lung. It transferred to my left lung about 30 mins later. It eventually disappeared about 30 minutes after that. The day of the lump and the next 3 days I had severe chest pain and difficulty catching my breath, accompanied by parts of my body going numb (hands, cheek), dizziness, and migraine. These symptoms have since gone away, but I am still having difficulty drawing a deep breath.
Pt's mother called 3/24/03 to report child had a temperature of 103 after shots. Child was taken to MD. MD gave antibiotics but continued to have fever on 3/22 and 3/23. On 3/24/03 child recovered and had no fever. Child did have a red puffy arm at DTaP injection site. Child woke up with temperature 3/20/03-he vomited the morning 3/20/03 when he had fever.
could not breath through nose; slowed movement; This spontaneous case was reported by a non-health professional and describes the occurrence of DYSPNOEA (could not breath through nose) and BRADYKINESIA (slowed movement) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 12L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included HYDROCHLOROTHIAZIDE, VALSARTAN (VALSARTAN/HYDROCHLOROTHIAZIDE) for an unknown indication.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced DYSPNOEA (could not breath through nose) and BRADYKINESIA (slowed movement). At the time of the report, DYSPNOEA (could not breath through nose) and BRADYKINESIA (slowed movement) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment included acetaminophen and nasal spray.  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to US-MODERNATX, INC.-MOD-2021-132703 (E2B Linked Report). This case was linked to MOD-2021-132703 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. US-MODERNATX, INC.-MOD-2021-132703:Case for second dose
This spontaneous report as received from a physician refers to a female patient of unknown age with no pertinent medical history and no drug reactions or allergies. On 04-AUG-2014, the patient was vaccinated with a dose of ZOSTAVAX strength reported as plaque-forming units (PFU) (dose, route and lot number were not reported). There were no concomitant medications. On 04-AUG-2014, the patient developed redness at the injection site which responded to unspecified treatment recommendations prescribed by the physician. On 07-AUG-2014, reported as today, the patient notified the physician that she had the following symptoms (started in August 2014, exact date not specified): itching all over her body, diarrhea and sore throat. The patient sought medical attention. The outcome of itching all over her body, redness at the injection site, diarrhea and sore throat was unknown. The relatedness between the events and ZOSTAVAX was not reported. Additional information has been requested.
Information has been received from a physician concerning a 4 year old female with no medical history who was vaccinated with a dose of varicella virus vaccine live. There was no concomitant medication. Subsequently, the patient experienced breakthrough varicella. She had less than 50 pox and a low grade fever. She was treated with 5 days of valacyclovir hydrochloride therapy, no laboratory tests were done and she recovered. The patient's experience was considered an other important medical event (OMIC). Additional information has been requested. Additional information has been received from personnel of the physician's office stating that they do not know the identity of the patient. No further information is available.
made me sick as a dog for 3 days; Initial information received on 13-Nov-2019 regarding an unsolicited valid non-serious case received via consume through social media  This case involves age patient who reported that, made me sick as a dog for 3 days (illness) while she received vaccine INFLUENZA VACCINE.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received dose of suspect INFLUENZA VACCINE lot number not reported via unknown route in the left arm.  On an unknown date, the patient reported that, made me sick as a dog for 3 days (illness) unknown latency following the administration of INFLUENZA VACCINE.  Other relevant tests included no lab data.  Final diagnosis was illness.  An unknown corrective treatment was received.  Event outcome was unknown.  There will be no information available on the batch number for this case.
Foggy feeling in head; Concentration impaired; Rash over arms; Itchy; Taste loss; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash over arms), PRURITUS (Itchy), AGEUSIA (Taste loss), FEELING ABNORMAL (Foggy feeling in head) and DISTURBANCE IN ATTENTION (Concentration impaired) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 and Hysterectomy. Concurrent medical conditions included Diabetes. Concomitant products included INSULIN for an unknown indication.   On 29-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-May-2021, the patient experienced RASH (Rash over arms), PRURITUS (Itchy) and AGEUSIA (Taste loss). On an unknown date, the patient experienced FEELING ABNORMAL (Foggy feeling in head) and DISTURBANCE IN ATTENTION (Concentration impaired). At the time of the report, RASH (Rash over arms), PRURITUS (Itchy), AGEUSIA (Taste loss), FEELING ABNORMAL (Foggy feeling in head) and DISTURBANCE IN ATTENTION (Concentration impaired) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment included Cortisone cream, Calamine lotion and Benadryl for itching.  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Severe pain in my upper back and shoulders. Went to the ER in case of blood clots. Had X-rays and blood/urine tests. Was given Toradol and Norco, but nothing changed. At home switching between heat/ice, and taking prescribed muscle relaxer. Not feeling much better after 12 hours.
spotting (minimal but not the timing she normallyexperiences spotting with her menstrual cycle); fever of 104.3; Headaches; severe body aches; This spontaneous case was reported by a consumer and describes the occurrence of INTERMENSTRUAL BLEEDING (spotting (minimal but not the timing she normallyexperiences spotting with her menstrual cycle)), PAIN (severe body aches), PYREXIA (fever of 104.3) and HEADACHE (Headaches) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Apr-2021, the patient experienced PYREXIA (fever of 104.3). On 11-Apr-2021, the patient experienced INTERMENSTRUAL BLEEDING (spotting (minimal but not the timing she normallyexperiences spotting with her menstrual cycle)). In April 2021, the patient experienced PAIN (severe body aches) and HEADACHE (Headaches). At the time of the report, INTERMENSTRUAL BLEEDING (spotting (minimal but not the timing she normallyexperiences spotting with her menstrual cycle)) had not resolved and PAIN (severe body aches), PYREXIA (fever of 104.3) and HEADACHE (Headaches) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Apr-2021, Body temperature: 104.3 (High) 104.3.         No concomitant medications were provided by the reporter.   Treatment information was not provided.
On 9-14-10 child was given immunization of Varicella and PCV-13 on right leg. 10 days later, on 9-24-10 mother noted redness, swelling knot at site. Went to ED. Fever 103.9. On 9/27 redness resolving.
Got vaccine on 1/15/21. He was tired right away, bedridden the next 3 days. He couldn't breathe so he was taken by ambulance on 1/18/21. He was in hospital for several days. put on remdesivir cocktail for 10 days. Slowly getting worse and died in hospital on 1/30/21.
Event occurred after 2nd vaccine. First vaccine was on 6/8/21 and the second one on 6/29/21. Pt tested positive for COVID-19 on  11/28/21. Unknown whether the pt received Pfizer or Moderna.
Patient received first shingrix vaccine on 9/21/19. On 12/4/19, patient was diagnosed with shingles by FNP-C. Provider requested that this adverse event be reported to VAERS.
Patient experienced syncope about 15 minutes post vaccination no other injuries were sustained. Squad was called and they came to check out patient and bring her to hospital if needed.  Patient had no other negative outcomes that were made known to pharmacy staff.
body ache; malaise; fever 101°F; Huge red patch; Itchiness; Arm pain; Headache; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of MALAISE (body ache; malaise) and PYREXIA (fever 101°F) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023M201 and 032L20A) for an unknown indication.     No relevant medical history was reported. The patient has no known allergies.  Concomitant products included LETROZOLE for Prophylaxis.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, the patient experienced MALAISE (body ache; malaise) and PYREXIA (fever 101°F). On 04-Mar-2021, MALAISE (body ache; malaise) and PYREXIA (fever 101°F) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In March 2021, Body temperature: 101 (High) 101 degrees Fahrenheit.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered MALAISE (body ache; malaise) and PYREXIA (fever 101°F) to be possibly related.    The patient is a physician who self-treated with ibuprofen 400mg on the second night and the events resolved.   This case was linked to MOD-2021-027515 (Patient Link).
Covid after second dose; Lack of drug effect; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Covid after second dose) and DRUG INEFFECTIVE (Lack of drug effect) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Apr-2021, the patient experienced COVID-19 (Covid after second dose) and DRUG INEFFECTIVE (Lack of drug effect). On 05-Apr-2021, DRUG INEFFECTIVE (Lack of drug effect) outcome was unknown. At the time of the report, COVID-19 (Covid after second dose) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Apr-2021, COVID-19: positive (Positive) positive.         No concomitant or treatment information was provided.  This is a case of lack of efficacy of the vaccine.  Based on the current available information and the mechanism of action of mRNA-1237 vaccine, the event of COVID-19 is assessed as not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 16-Apr-2021: Upon internal review on 06-Aug-2021, event of Lack of drug effect was added.; Sender's Comments: This is a case of lack of efficacy of the vaccine.  Based on the current available information and the mechanism of action of mRNA-1237 vaccine, the event of COVID-19 is assessed as not applicable.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information provided. No treatment medication information provided.
Headache, chills with fever 101F X 24hrs, whole body aches, fatigue
This retrospective pregnancy case was reported by a consumer via call center representative and described the occurrence of fetal demise in a 37-year-old female patient who received FLULAVAL QUADRIVALENT 2018-2019 season for prophylaxis. In November 2018, the patient received FLULAVAL QUADRIVALENT 2018-2019 season. The patient's last menstrual period was on an unknown date and estimated date of delivery was on an unknown date. The patient received FLULAVAL QUADRIVALENT 2018-2019 season at week 7 of the pregnancy and during the first trimester of pregnancy. In November 2018, 2 days after receiving FLULAVAL QUADRIVALENT 2018-2019 season, the patient experienced muscle stiffness. On an unknown date, the patient experienced fetal demise (serious criteria hospitalization and GSK medically significant), spotting menstrual (serious criteria hospitalization) and vaccine exposure during pregnancy. FLULAVAL QUADRIVALENT 2018-2019 season was continued with no change. On an unknown date, the outcome of the fetal demise, spotting menstrual, muscle stiffness and vaccine exposure during pregnancy were unknown. The pregnancy ended in a spontaneous abortion at less than 22 weeks gestation with no apparent congenital anomaly present. It was unknown if the reporter considered the fetal demise, spotting menstrual and muscle stiffness to be related to FLULAVAL QUADRIVALENT 2018-2019 season. Additional details were provided as follows: The patient received vaccine on left deltoid. The patient was 7 weeks and 2 days pregnant when she had her first ultrasound. The fetus had a normal heartbeat. After receiving FLULAVAL QUADRIVALENT 2018-2019 season, she had menstrual spotting during the 10th week of pregnancy and the fetus had no heartbeat at the end of the 11th week. She was diagnosed with fetal demise retrospectively during the 8th week of pregnancy.